<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assessing asthma control in youths greater than or equal to 12 years of age and adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assessing asthma control in youths greater than or equal to 12 years of age and adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Assessing asthma control in youths greater than or equal to 12 years of age and adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup> <colgroup span="4" width="22.5%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2" rowspan="2">Components of control</td> <td class="subtitle1" colspan="3">Classification of asthma control (youths ≥12 years of age and adults)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Well-controlled</td> <td class="subtitle2">Not well-controlled</td> <td class="subtitle2">Very poorly controlled</td> </tr> <tr> <td rowspan="6">Impairment</td> <td>Symptoms</td> <td>≤2 days/week</td> <td>&gt;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>≤2 times/month</td> <td>1 to 3 times/week</td> <td>≥4 times/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>≤2 days/week</td> <td>&gt;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td>FEV<sub>1</sub> or peak flow</td> <td>&gt;80% predicted/personal best</td> <td>60 to 80% predicted/personal best</td> <td>&lt;60% predicted/personal best</td> </tr> <tr class="divider_bottom"> <td>Validated questionnaires</td> <td> <ul> <li>ATAQ = 0</li> <li>ACQ ≤0.75<sup>*</sup></li> <li>ACT ≥20</li> </ul> </td> <td> <ul> <li>ATAQ = 1 to 2</li> <li>ACQ ≥1.5</li> <li>ACT = 16 to 19</li> </ul> </td> <td> <ul> <li>ATAQ = 3 to 4</li> <li>ACQ = N/A</li> <li>ACT ≤15</li> </ul> </td> </tr> <tr> <td rowspan="4">Risk</td> <td rowspan="2"><strong>Exacerbations</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan="2"><strong>≥2/year (refer to legend)</strong></td> </tr> <tr> <td colspan="3"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td>Progressive loss of lung function</td> <td colspan="3">Evaluation requires long-term follow-up care</td> </tr> <tr> <td>Treatment-related adverse effects</td> <td colspan="3">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> </tbody></table></div><div class="graphic_lgnd">The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of the previous 2 to 4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not well-controlled asthma, even in the absence of impairment levels consistent with not well-controlled asthma.</div><div class="graphic_footnotes"><p>ACQ: Asthma Control Questionnaire (Juniper et al. 1999b); ACT: Asthma Control Test (Nathan et al. 2004); ATAQ: Asthma Therapy Assessment Questionnaire (Vollmer et al. 1999); EIB: exercise-induced bronchospasm; FEV<sub>1</sub>: forced expiratory volume in 1 second; N/A: not applicable. </p>
* ACQ values of 0.76 to 1.4 are indeterminate regarding well-controlled asthma.</div><div class="graphic_reference">Adapted from: National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 07-4051NIH, National Heart, Lung, and Blood Institute, Bethesda, MD 2007.</div><div id="graphicVersion">Graphic 65972 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
